Nucleic acid sequencing

[1]  A. Prat,et al.  Frequency and spectrum of PIK3CA somatic mutations in breast cancer , 2020, Breast Cancer Research.

[2]  M. Fournier,et al.  Methylation profiling in promoter sequences of ATM and CDKN2A (p14ARF/p16INK4a ) genes in blood and cfDNA from women with impalpable breast lesions. , 2020, Oncology letters.

[3]  R. Hastings,et al.  Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer , 2019, Breast Cancer Research.

[4]  David R. Jones,et al.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.

[5]  Yan Liu,et al.  p53 involvement in clonal hematopoiesis of indeterminate potential. , 2019, Current opinion in hematology.

[6]  K. Page,et al.  The liquid biopsy: towards standardisation in preparation for prime time. , 2019, The Lancet. Oncology.

[7]  H. Nielsen,et al.  Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.

[8]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[9]  S. Shchegrova,et al.  Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence , 2019, Clinical Cancer Research.

[10]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[11]  T. Yeatman,et al.  Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. , 2018 .

[12]  F. Clatot,et al.  Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients , 2018, Breast Cancer Research.

[13]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[14]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[15]  D. Brinza,et al.  Abstract 5396: An NGS workflow to detect down to 0.1% allelic frequency in cfDNA for breast and colon cancers , 2017 .

[16]  Jorge S. Reis-Filho,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[17]  Allison Hills,et al.  Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.

[18]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[19]  Sung-Bae Kim,et al.  NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer , 2014, Breast Cancer Research and Treatment.

[20]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[21]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[22]  Nathalie Zahra,et al.  Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids , 2013, PloS one.

[23]  A. Howell,et al.  Edinburgh Research Explorer Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 random , 2013 .

[24]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[25]  Karen Page,et al.  Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.

[26]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[27]  C. D'Orsi,et al.  Influence of computer-aided detection on performance of screening mammography. , 2007, The New England journal of medicine.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[29]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.